Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease, is sponsoring a clinical trial — with a study site in Scottsdale — for a promising new investigational treatment for Alzheimer’s disease.

The phase one study will determine the safety and tolerability of a single intravenous dose and multiple IV doses of ACU193, according to a press release.

Acumen is asking individuals who have memory problems to consider participating in the trial to assist in evaluating this investigational medication for the treatment of Alzheimer’s disease. There is no cost to participate.

ACU193 targets toxic amyloid-beta oligomers and is a different approach to treating Alzheimer’s disease than currently approved medications, the release stated. ACU193 is designed to locate and bind to amyloid-beta oligomers — proteins that build up in the brain in people with Alzheimer’s disease.

As further explained in the release, these proteins are thought to be involved in Alzheimer’s disease symptoms and progression.

The trial site is located at Clinical Endpoints, 9977 N. 95th St, Suite 101. Clinical Endpoints is led by medical director, Constantine Moschonas, MD.

“We’re excited to open this trial in Scottsdale to study ACU193 for the treatment of Alzheimer’s disease,” Moschonas stated in the release. “If you or a loved one is experiencing memory problems, contact us to find out more about the study. More than 6 million Americans are living with Alzheimer’s disease; new, safe and effective treatments are needed more than ever. Participating in clinical trials is one-way members of our community can help make a difference.”

Key eligibility criteria:

• Age 55 to 90 years of age.
• Have memory problems that might be a sign of mild cognitive impairment (usually mild memory loss) or mild dementia. The underlying cause of these memory problems may or may not be due to Alzheimer’s disease. Tests given within the study will help to determine this.
• Have a caregiver or study partner; someone who knows the participant well, who is willing to assist with participation in the study and can attend the study visits with the participant.
• The staff at the study center will explain the complete list of requirements.

Patients who believe they qualify for the study are asked to contact Lizzie Yungson or Lori Hane, via phone number 480-566-9090 or email eyoungson@clinicalendpoints.com or visit www.clinicalendpoints.com to learn more.

This study is the first time ACU193 will be given to people. As all drugs and medical procedures carry a risk of side effects, it is possible that participants may experience some discomfort or other reactions from use of ACU193, the release stated.

The study staff will explain these potential risks before potential participants decide whether to participate in the study, and safety of participants will be closely monitored throughout the study.

According to the release, study participants will receive a full diagnostic work-up, including an amyloid PET scan and MRI that can provide a more accurate diagnosis and help guide future treatment options. There will be no out of pocket costs for the participant.

After finishing this study, participants may consider participating in future studies of ACU193 in which all participants could receive ACU193 at some point in the study, the release stated.